Phoenix Group (LON:PHNX – Free Report) had its price target upped by Berenberg Bank from GBX 850 to GBX 852 in a research note issued to investors on Monday, MarketBeat Ratings reports. Berenberg Bank currently has a buy rating on the stock.
Other equities analysts have also issued reports about the stock. UBS Group reissued a “neutral” rating and set a GBX 630 price target on shares of Phoenix Group in a research report on Friday, September 5th. Royal Bank Of Canada reduced their price target on shares of Phoenix Group from GBX 725 to GBX 690 and set an “outperform” rating for the company in a research report on Thursday, July 24th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of GBX 684.25.
Check Out Our Latest Stock Report on PHNX
Phoenix Group Stock Down 0.1%
Phoenix Group (LON:PHNX – Get Free Report) last posted its quarterly earnings results on Monday, September 8th. The company reported GBX (18.20) earnings per share (EPS) for the quarter. Phoenix Group had a negative return on equity of 21.76% and a negative net margin of 2.10%. Sell-side analysts forecast that Phoenix Group will post 51.179941 earnings per share for the current year.
About Phoenix Group
Phoenix is the UK’s largest long-term savings and retirement business with c. £300 billion of assets under administration and c. 12 million customers.
We are a constituent of the FTSE 100 with c. 7,800 colleagues and offer a broad range of products to support people across all stages of the savings life cycle.
We are a growing and sustainable business with a clear purpose – helping people secure a life of possibilities.
Featured Stories
- Five stocks we like better than Phoenix Group
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Investing In Preferred Stock vs. Common Stock
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- How to Read Stock Charts for Beginners
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Phoenix Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Group and related companies with MarketBeat.com's FREE daily email newsletter.